Key clinical point: Keloids, which could be formed via Th2 pathogenesis, may be treatable with dupilumab.
Major finding: Interleukin-4 receptors, which are directly targeted by dupilumab, were highly up-regulated in keloid lesions, compared with controls (P less than .1).
Study details: A study of three black patients with severe chronic keloids and no atopic dermatitis and five black controls.
Disclosures: Four authors had no disclosures. Two authors reported numerous disclosures, including receiving grants, research funds, and personal and consulting fees, from various pharmaceutical companies, including dupilumab manufacturers Regeneron and/or Sanofi.
Diaz A et al. J Eur Acad Dermatol Venereol. 2019 Nov 20. doi: 10.1111/jdv.16097.